4 Precision Medicine Data Platforms Rewriting Oncology Protocols in 2026

The US National Institutes of Health's All of Us Research Program surpassed 1 million genomic participants in January 2026 becoming the world's most diverse precision medicine dataset and simultaneously announced partnerships with five major oncology centers to use the database for AI-powered cancer subtype identification, a development that is reshaping how oncologists in Boston, Houston, and San Francisco approach treatment selection for molecularly heterogeneous tumor types.

Whole Genome Sequencing Enters Routine Clinical Oncology at Major US Centers

Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and MD Anderson Cancer Center have each announced in Q1 2026 the transition of whole genome sequencing from research to routine clinical ordering for newly diagnosed cancer patients presenting with solid tumors. This transition enabled by sequencing costs falling below $500 per genome and turnaround times below 10 days produces molecular profiles that identify actionable mutations, tumor mutational burden, and microsatellite instability status simultaneously in a single test, replacing panels of sequential molecular tests that previously took weeks and cost more in aggregate. The clinical workflow integration of whole genome sequencing is fundamentally altering what oncologists know about their patients' tumors at the point of initial treatment planning, directly enabling more precise first-line treatment selection and reducing the trial-and-error progression through treatment lines that has historically characterized oncology care. This capability advancement is central toprecision oncology digital health platformdevelopment strategies across major cancer center networks.

Regional Digital Health Intelligence

US Digital Health UK Digital Health Germany Digital Health France Digital Health Japan Digital Health South Korea Digital Health China Digital Health India Digital Health GCC Digital Health Italy Digital Health Spain Digital Health South America Digital Health

UK Genomics England Expands to 5 Million Whole Genome Sequences

Genomics England's National Genomic Healthcare System operating through the NHS Genomic Medicine Service has sequenced its 5 millionth whole genome as of January 2026, making the UK's linked genomic-clinical dataset the largest in the world relative to national population size. The dataset now covers approximately 7 percent of the UK population with linked primary care records, hospital episode statistics, cancer registry data, and prescription histories creating the depth of real-world clinical context that AI researchers require to translate genomic signals into actionable clinical predictions. NIH and Genomics England researchers have identified 12 new pharmacogenomic variants in the 2025 dataset with direct clinical implications for oncology drug dosing, findings that are being incorporated into NICE pharmacogenomic testing guidance that will affect prescribing across the NHS. The operational depth of this dataset is advancing the evidence base forUK digital health genomic medicine infrastructurethat positions the NHS as the world's foremost real-world genomic research environment.

China's Precision Medicine Initiative Links Genomic Data to 40 Million EHR Records

China's National Precision Medicine Initiative operating under the 14th Five-Year Plan's healthcare technology priorities has completed linkage of genomic sequencing data from 3 million participants with electronic health records from 40 million patients across China's national health information platform. The scale of this linked dataset enables machine learning models to identify genomic predictors of treatment response, drug toxicity, and disease progression across tumor types that are predominantly prevalent in China including nasopharyngeal carcinoma, hepatocellular carcinoma, and gastric cancer but that are underrepresented in Western genomic databases. Chinese oncology AI companies including LinkDoc Technology and Yidu Cloud are developing clinical decision support tools trained on this linked dataset, building precision oncology capabilities specifically calibrated for Chinese patient populations rather than adapted from Western genomic references. The breadth of the linked data is a key competitive asset forChina digital health precision medicine innovationin oncology globally.

South Korea's K-Genome Project Delivers Pharmacogenomic Database for 500,000 Patients

South Korea's Korean Genome Project has delivered a comprehensive pharmacogenomic variant database derived from 500,000 Korean participants, providing the clinical genomics community with the most complete reference dataset for Korean population pharmacogenomics available globally. The database is integrated with South Korea's Health Insurance Review and Assessment Service claims data, enabling correlation of pharmacogenomic variants with real-world prescribing outcomes across a population that is relatively genetically homogeneous compared to admixed Western populations providing statistical power for pharmacogenomic signal detection that diverse populations require much larger sample sizes to achieve. South Korean hospitals are deploying pharmacogenomic testing guided by this database for oncology, cardiology, and psychiatry treatment selection, advancing the clinical application ofSouth Korea digital health precision medicine programsbeyond genomic data collection into routine clinical utilization.